🚀 Future Outlook
ITGB6 is a promising target for overcoming immunotherapy resistance and treating aggressive epithelial cancers. New ADCs and bispecifics are paving the way for smarter, combo-friendly treatments.
#ITGB6 #integrin αVβ-6 #sigvotatug vedotin #cancer cell invasion #JSKN022 #lifesciences #Mabnus #Biology
Comments